申请人:SUNTORY LIMITED
公开号:EP0798304A1
公开(公告)日:1997-10-01
Compounds represented by the general formula (I) or pharmacologically acceptable salts thereof:
(where R is a group -NHCHR1R2, -N(CHR1R2)2, -N(CHR1R2)CHR3R4, -N+(CHR1R2)3, -N+(CHR1R2)2CHR3R4 or -N+(CHR1R2)(CHR3R4)CHR5R6 (where R1, R2, R3, R4, R5 and R6, which may be the same or different, are each a hydrogen atom, an alkyl group, an alkenyl group, an aryl group or an aralkyl group, or an alkyl, alkenyl, aryl or aralkyl group which is substituted by at least one substituent selected from the group consisting of a halogen atom, a hydroxyl group, a lower alkoxy group, a lower alkylacyloxy group, a lower alkylacyl group, a lower alkoxycarbonyl group, a nitro group, a cyano group and a heterocyclic group, with CHR1R2, CHR3R4 or CHR5R6 optionally forming a cyclic alkyl group, provided that when R is -N(CHR1R2)CHR3R4, -N+(CHR1R2)2CHR3R4 or -N+(CHR1R2)(CHR3R4)CHR5R6, CHR1R2, CHR3R4 and CHR5R6 are different groups); therapeutics for thrombocytopenia containing them as an effetive ingredient; as well as intermediates for their synthesis and processes for producing them.
通式(I)代表的化合物或其药理上可接受的盐类:
(其中 R 是基团 -NHCHR1R2、-N(CHR1R2)2、-N(CHR1R2)CHR3R4、-N+(CHR1R2)3、-N+(CHR1R2)2CHR3R4 或 -N+(CHR1R2)(CHR3R4)CHR5R6(其中 R1、R2、R3、R4、R5 和 R6 可以相同或不同,各为氢原子、烷基、烯基、芳基或芳烷基,或至少被一个取代基取代的烷基、烯基、芳基或芳烷基,该取代基可从卤素原子组成的组中选出、羟基、低级烷氧基、低级烷酰氧基、低级烷酰基、低级烷氧羰基、硝基、氰基和杂环基、CHR3R4或CHR5R6可选地形成环状烷基,条件是当R为-N(CHR1R2)CHR3R4、-N+(CHR1R2)2CHR3R4或-N+(CHR1R2)(CHR3R4)CHR5R6时,CHR1R2、CHR3R4和CHR5R6为不同的基团);含有它们作为有效成分的血小板减少治疗药物;以及合成它们的中间体和生产它们的工艺。